Schizophrenia Daily News Blog

Titan initiates phase III trial for iloperidone

Titan pharmaceuticals has initiated a Phase III clinical study of iloperidone (Zomaril), Titan's proprietary antipsychotic agent licensed to Vanda and in development for the treatment of schizophrenia and related disorders. The study is designed as a randomized, double blind, controlled, three arm study. Patients in this multi-center study will receive iloperidone, placebo, or an active control. The study is designed to assess the efficacy, safety and tolerability of iloperidone in schizophrenic patients in acute exacerbation. The primary endpoint of the study is the reduction in the symptoms of schizophrenia as assessed by the Positive and Negative Symptom Scale (PANSS).

In a related news release, R&D Drug Focus News stated that "Iloperidone, a dopamine-D2/5HT2 antagonist which acts as an antipsychotic via mesolimbic activity, was originally developed by Hoechst Marion Roussel (now known as Sanofi-Aventis), from which Titan acquired exclusive worldwide rights from in January 1997. Vanda subsequently acquired exclusive worldwide rights from sub-licensee Novartis in June 2004."

Source: Titan Pharmaceuticals, R&D Drug Focus News